Published in final edited form as:

Horm Cancer. 2014 August ; 5(4): 218–231. doi:10.1007/s12672-014-0184-z.

Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells

Melanie M. Scully¹, Leslie K. Palacios-Helgeson¹, Lah S. Wah¹, and Twila A. Jackson¹

Melanie M. Scully: melanie.scully@UCDenver.edu; Leslie K. Palacios-Helgeson: leslie.palacios-helgeson@UCDenver.edu; Lah S. Wah: lah.wah@UCDenver.edu; Twila A. Jackson: Twila.Jackson@UCDenver.edu

¹Department of Basic Reproductive Sciences, University of Colorado Denver, Anschutz Medical Center, Aurora, CO 80045, USA

Abstract

Hyperestrogenicity is a risk factor for endometrial cancer. 17 β -estradiol (E2) is known to stimulate both genomic and nongenomic estrogen receptor- α (ER α) actions in a number of reproductive tissues. However, the contributions of transcription-independent ER α signaling on normal and malignant endometrium are not fully understood. Phosphatase and tensin homolog (PTEN) is a tumor suppressor that decreases cellular mitosis primarily through negative regulation of the phosphoinositide 3-kinase/AKT signaling axis. PTEN levels are elevated during the E2 dominated, mitotically active, proliferative phase of the menstrual cycle, indicating possible hormonal regulation of PTEN in the uterus. In order to determine if rapid E2 signaling regulates PTEN, we used ER α positive, PTEN positive, endometrial cells. We show that cytosolic E2/ER α signaling leads to increased phosphorylation of PTEN at key regulatory residues. Importantly, E2 stimulation decreased PTEN lipid phosphatase activity and caused consequent increases in phospho-AKT. We further demonstrate that cytosolic ER α forms a complex with PTEN in an E2-dependent manner, and that ER α constitutively complexes with protein kinase2- α (CK2 α), a kinase previously shown to phosphorylate the C-terminal tail of PTEN. These results provide mechanistic support for an E2-dependent, ER α cytosolic signaling complex that negatively regulates PTEN activity through carboxy terminus phosphorylation. Using an animal model, we show that sustained E2 signaling results in increased phospho-PTEN (S380, T382, T383), total PTEN and phospho-AKT (S473). Taken together, we provide a novel mechanism in which transcription-independent E2/ER α signaling may promote a pro-tumorigenic environment in the endometrium.

Keywords

estrogen receptor; phospho-PTEN; endometrial cancer; nongenomic; phospho-AKT

Introduction

Endometrial cancer (EC) is the most common gynecologic cancer and the fourth most common cancer in women in the U.S. [57]. The American Cancer Society estimates that

Conflict of Interest The authors declare that they have no conflict of interest.

52,630 new cases will be diagnosed in 2014 and 8,590 women will die from this disease [4]. Eighty percent of EC are Type I and are characterized by expression of estrogen receptor (ER) [48, 36, 18, 12]. There are three main forms of estrogen, estrone (E1), 17 β -estradiol (E2) and estriol (E3). In the non-pregnant uterus, (E2) is the dominant regulatory estrogen. Unopposed, chronic or excess exposure to estrogens, including E2 and the adipocyte produced E1, are the main risk factors for Type I EC [26].

E2 acting through ER α provides the primary proliferative signal in the uterine epithelium, and hyperestrogenicity is a major risk factor for EC [21, 23]. Traditionally, ER α has been thought of as ligand-dependent transcription factor that influences gene regulation. However, increasing evidence implicates transcription-independent actions of ER α in both normal and pathological processes [8, 50, 37, 44]. Transcription-independent ER α signaling is involved in regulation of proliferation [62] and cytoskeletal remodeling [2]. Additionally, non-nuclear ER α signaling has been implicated in invasion, migration and metastasis in hormone sensitive breast cancer cells [15, 14, 7, 68]. Emerging data highlights the importance of rapid actions of estrogens, however, the role of transcription-independent E2 signaling in the endometrium and in EC is poorly understood.

During the normal menstrual cycle, PTEN levels fluctuate, suggesting that tumor suppressor PTEN is regulated by hormones in the endometrium [38]. PTEN regulates growth in normal cells via its lipid phosphatase activity. Specifically, PTEN antagonizes the phosphoinositide 3-kinase (PI3K)/Akt survival and growth pathway by converting phosphatidylinositol (3,4,5)-trisphosphate (PIP₃) to phosphatidylinositol 4,5-bisphosphate (PIP₂) to decrease available PIP₃ for downstream signaling [33, 52, 53, 29].

PTEN phosphatase activity is regulated through oxidation [28], acetylation [40], ubiquitination [32] and phosphorylation [58, 39]. Phosphorylation at three key regulatory sites on the C-terminus of PTEN (S380, T382, T383) has been shown to decrease lipid phosphatase activity [58]. Decreased PTEN activity and consequent increased AKT signaling result in increased proliferation, inhibition of apoptosis, and resistance to progestin therapy [51]. Stimuli that induce phosphorylation of PTEN may therefore confer shifts in PTEN activity, which have been shown to cause endometrial hyperplasia and uterine dysplasia *in vivo* [3].

The normal endometrium cycles between periods of dramatic proliferation and differentiation in response to changing hormone levels. Unexpectedly, work from two different labs shows that PTEN protein levels are the highest in uterine epithelial cells during the pro-growth, E2-dominated, proliferative phase of the menstrual cycle [38, 1]. However, in these studies PTEN phosphorylation status and correlative activity was not assessed. Additionally, direct hormonal regulation of PTEN activity in the endometrium has not been investigated.

In normal cycling endometrial tissues, high levels of PTEN may be protective against potential aberrant proliferation, while low PTEN activity allows growth of the uterine lining. We hypothesize that E2 rapidly signals to key negative regulatory residues in the carboxy terminus of PTEN to suppress PTEN activity. We anticipate that risk factors for uterine

cancer, which result in increased, chronic or unopposed E2 exposure, cause an abnormal reduction in PTEN activity. Reduced PTEN activity and associated upregulation of AKT signaling promote cellular processes that contribute to a pro-cancer environment. As normal endometrial cell models are not available [27], we initially conducted molecular and biochemical studies using engineered EC cell models to determine if E2 signaling impacts PTEN phosphorylation and activity.

Materials and Methods

Cell Culture

Ishikawa EC cells and 293TN cells were obtained from American Type Culture Collection (Manassas, VA). Cells were cultured in Dulbecco's modified Eagle medium (DMEM) (Fisher Scientific, Pittsburgh, PA) supplemented with 10% v/v fetal calf serum (Thermo Scientific, Rockford, IL) and 50 µg/mL penicillin and streptomycin (Mediatech Inc., Manassas, VA). Cells were maintained at 37°C in 5% CO₂.

Antibodies and 17β-estradiol

Rabbit anti-PTEN, phospho-PTEN (S380, T382, T383), AKT, β-actin and GAPDH as well as mouse anti-phospho-AKT (S473) were purchased from Cell Signaling Technologies (Danvers, MA). Mouse anti-protein kinase CK2α was purchased from Millipore (Billerica, MA). Mouse anti-ERα, rabbit anti-ERα and rabbit anti-ERβ were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX). Rabbit anti-GPER antibody was supplied by GenScript USA Inc. (Piscataway, NJ). IRDye conjugated secondary antibodies used in western immunoblotting are from LI-COR Biosciences (Lincoln, NE) while HRP conjugated secondary antibodies used in western immunoblotting are from Cell Signaling Technologies (Danvers, MA). 17β-estradiol was diluted in 200 proof ethanol (Fisher Scientific, Pittsburgh, PA) and used at a final concentration of 10 nM (Sigma-Aldrich, St. Louis, MO).

17β-estradiol treatment

Cells at 80% confluence were starved for 24 hours in serum free media (phenol red free DMEM, Thermo Scientific, Rockford, IL) supplemented with 50 µg/mL penicillin and streptomycin (Mediatech Inc., Manassas, VA). Cells were then treated with either 10 nM 17β-estradiol (Sigma-Aldrich, St. Louis, MO) or vehicle (100% ethanol) (Fisher Scientific, Pittsburgh, PA) for 0, 10, 30 or 50 minutes. Unless otherwise noted, all experiments were conducted as described here.

Western immunoblotting

Cells were harvested in Laemmli's SDS sample buffer (Bio-Rad, Hercules, CA) for western blot analysis. Protein concentration was assessed using the bicinchoninic acid (BCA) assay following the manufacturer's instructions (Thermo Scientific, Rockford, IL). Proteins were resolved by 10% SDS polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane (Bio-Rad, Hercules, CA). Western blotting was performed as per standard protocols provided by the antibody manufacturer. When IRDye conjugated secondary antibodies were used, resultant membranes were scanned by Odyssey CLx (LI-COR

Biosciences, Lincoln, NE). Quantification was completed using Odyssey CLx software (LI-COR Biosciences, Lincoln, NE). When HRP conjugated secondary antibodies were used, densitometry was used to quantify developed x-ray films (ISC BioExpress, Kaysville, UT) using Bio-Rad Analyzer Quantity One software (Bio-Rad, Hercules, CA).

Cellular fractionation

One million cells were fractionated with NE-PER Nuclear and Cytoplasmic extraction kit following the manufacturer's instructions (Thermo Scientific, Rockford, IL).

PTEN immunoprecipitation and lipid phosphatase assay

Cells were harvested in phosphate free non-denaturing buffer (20 mM Tris base, pH 7.4, 150 mM NaCl, 1mM EGTA, 1% v/v Triton X-100). Protein G sepharose beads (GE Healthcare Life Sciences, Piscataway, NJ) were pre-incubated with 3% bovine serum albumin (Fisher Scientific, Pittsburgh, PA) for 1 hour and washed in phosphate free non-denaturing buffer. After pre-incubation, 2.5 µg of antibody and cell lysates were added to beads and incubated end-over-end for 1 hour at 4 °C. Cells were washed in phosphate free non-denaturing buffer and centrifuged at 8,000 g for 5 minutes at 4 °C followed by PTEN phosphatase assay. PTEN lipid phosphatase activity was assessed using the PTEN Malachite Green Assay (Echelon Biosciences Inc., Salt Lake City, UT). Briefly, immunoprecipitated PTEN was incubated with PtdIns(3,4,5)P₃ substrate for 15 minutes at 37 °C in a buffer containing malachite green molybdate (Echelon Biosciences Inc., Salt Lake City, UT). Free phosphate was observed via formation of green molybdophosphoric acid complex and absorbance at 620 nm was measured. Free phosphate (pmol) was determined by interpolation from a standard curve.

Co-immunoprecipitation

Ten million cells were harvested and lysates were prepared in non-denaturing buffer (50 mM Tris-HCL pH 7.4, 1% v/v NP-40, 0.5% v/v Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 50 mM NaF). Lysates were pre-cleared by 1 hour incubation with protein G sepharose beads (GE Healthcare Life Sciences, Piscataway, NJ). Lysates were incubated with 2.5 µg of antibody at 4 °C overnight. Blocked (3% BSA x 1 hour) protein G sepharose beads (GE Healthcare Life Sciences, Piscataway, NJ) were added to the lysate + antibody mixture and incubated for 1 hour at 4 °C. Beads were washed in non-denaturing buffer and centrifuged at 8,000 g for 5 minutes at 4 °C. Laemmli's SDS sample buffer (Bio-Rad, Hercules, CA) was then added to the samples for western blot analysis.

Transfections

One million EC cells were transfected with Lipofectamine 2000 following manufacturer's instructions (Life Technologies, Grand Island, NY). A 1:4 ratio of DNA to Lipofectamine 2000 transfection reagent was used. For transient transfections, pGZ21-GFP-PTEN expression plasmid or empty PGZ21-GFP control plasmid was used. pGZ21 contains a CMV promoter and a GFP coding sequence with three amino acid residue substitutions (S65A, V68L, and S72A) to increase its fluorescence in mammalian cells [9]. Cells incubated in transfection mix for 6 hours. Eight million 293TN cells were transfected with

Lipofectamine 2000 following manufacturer's instructions. A 1:1:10 ratio of DNA to pPACKH1 lentiviral packaging DNA to Lipofectamine 2000 was used (Systems Biosciences, Mountain View, CA). Cells incubated in transfection mix for 48 hours.

Lentiviral constructs

PTEN sequence was removed from pIND/hygro plasmid (Life Technologies, Grand Island, NY) via digest with BamHI and NotI and cloned into the lentiviral expression vector pCDH-CMV-MCS-EF1-copGFP (System Biosciences, Mountain View, CA). Lentiviral particles were produced in 293TN packaging cells. Media containing packaged virus was collected 48 and 72 after transfection. Ten million EC cells were incubated with 20 ml of DMEM media containing viral particles. After 72 hours, puromycin selection was initiated (5ug/ml). Puro selection was carried out for 3 days and cells were diluted into 96 well cell culture dishes at an estimated frequency of 1 cell/well (Thermo Scientific, Rockford, IL). GFP-positive single clones were identified and expanded. Clones were screened for PTEN expression via western blot.

Experimental animals

Mouse experiments were conducted as previously described [46, 17]. Briefly, ovariectomized female athymic *nu/nu* mice were obtained from Harlan Sprague-Dawley (Indianapolis, IN) at 5 to 6 weeks of age. All animals were implanted with silastic pellets containing 17 β -estradiol (2 mg 17h-estradiol + 8 mg cellulose) or placebo (10 mg cellulose) [47]. Pellets resulted in 145 ± 47 pg/mL circulating estradiol. At 8 weeks mice were euthanized by CO₂ asphyxiation, and uteri were excised and prepared for immunohistochemistry.

Immunohistochemistry

Formalin fixed paraffin embedded tissues were sectioned at 5 μ m and mounted onto positively charged slides (Fisher Scientific, Pittsburgh, PA). Samples were de-paraffinized and re-hydrated through descending series of ethanol/water baths. Tissues were antigen retrieved in citrate buffer, pH 6 (16 mM sodium citrate trisodium salt dihydrate and 4 mM citrate acid monohydrate). Samples were blocked with 5% bovine serum albumin w/v in SuperBlock (Fisher Scientific, Pittsburgh, PA) followed by overnight incubation at 4 °C with primary antibody specific to phospho-PTEN (S380, T382, T383) (Abcam, Cambridge, MA), total PTEN or phospho-AKT (S473) (Cell Signaling, Danver, MA). Primary antibodies were diluted 1:100, 1:100 and 1:50, respectively, in Signal Stain Antibody Diluent (Cell Signaling, Danvers, MA). Negative control slides were performed by omitting the primary antibody. Slides were rinsed in IHC wash buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.1% Tween-20 v/v) and incubated with HRP-conjugated Rabbit Signal Boost (Cell Signaling, Danvers, MA) for 30 minutes. Immunopositive cells were visualized by addition of a 3,3-diaminobenzidine substrate (Vector Labs, Burlingame, CA), rinsed with IHC wash buffer and counterstained with hematoxylin (Sigma-Aldrich, St. Louis, MO). Samples were dehydrated through ascending series of water/ethanol baths followed by incubation in xylene (Sigma-Aldrich, St. Louis, MO). Slides were mounted with permount mounting media (Sigma-Aldrich, St. Louis, MO).

Quantification of immunohistochemistry

Quantification of phospho-PTEN, total PTEN and phospho-AKT immunohistochemistry was performed using NIS-Elements Imaging Software (Nikon Microscopes, Melville, NY). Uteri from a minimum of 6 ovariectomized mice and 9 E2 treated mice were analyzed. At least 3 uterine glands per mouse uterus were analyzed. Uterine glands were manually outlined and identified as regions of interest (ROI) for NIS-Elements Imaging Software analysis. Threshold measurements of immunopositive staining were applied to each ROI to measure protein abundance. The sum intensity measurement (SI) of positive staining in each identified gland (ROI) was divided by gland area in order to measure sum intensity per unit area (SI/mm²).

Statistical Analysis

Data are expressed as change $\pm$ standard deviation. Data were analyzed with Student *t* test between two groups of analysis of variance (ANOVA) coupled with Dunnett's Multiple Comparison Test for multiple pairwise comparisons. Probability values of $P < 0.05$ were considered to be statistically significant.

Results

E2 regulates PTEN phosphorylation, protein stability, and lipid phosphatase activity

Seminal studies conducted by Vazquez et al. identified S380, T382 and T383 as key negative regulatory residues in the PTEN carboxy tail [58]. Phosphorylation of these residues resulted in decreased PTEN lipid phosphatase activity and increased protein stability [58]. However, specific stimuli that induce PTEN phosphorylation *in vivo* were not investigated. In order to determine if E2 signaling induced phosphorylation of PTEN carboxy terminal regulatory residues, we utilized ER α wild type, Type1 Ishikawa endometrial cells (ISH-ER α _{WT}). As ISH-ER α _{WT} cells are PTEN null, we first transiently transfected cells with either an empty GFP-fusion vector or a GFP-PTEN expression construct. The transfected cells were starved in serum free media for 24 hours, stimulated with 10 nM E2 and harvested over a 50 minute time course for western blot analysis. The western blot in Figure 1A shows that E2 induced phosphorylation of S380, T382, T383 over the time course, as assayed by a phospho-specific PTEN antibody. The corresponding graph shows the average of phospho-PTEN normalized to the β -actin loading control in 3 independent experiments. E2 treatment induced a 2-fold, statistically significant increase in PTEN phosphorylation at 30 and 50 minutes. Using a pan-PTEN antibody, we also observed a concurrent increase in total PTEN protein levels, indicating increased PTEN stability (Figure 1B). These data are consistent with the original phospho-PTEN mapping studies conducted by Vazquez et al., which demonstrated that PTEN stability is governed by phosphorylation at S380, T382, T383 [58]. We have further observed that inhibiting PTEN phosphorylation blocks E2-induced PTEN protein stability (Supplemental Figure 1). Therefore, increased PTEN stability requires E2-induced PTEN phosphorylation. Similar experiments were conducted in MCF7 breast cancer cells. E2 treatment also leads to increased PTEN phosphorylation and PTEN protein stability in MCF7 cells, suggesting that E2 regulation of PTEN may occur in a variety of hormonally responsive tissues (Supplemental Figure 2).

In order to determine if changes in PTEN phosphorylation affected activity, we performed an immunoprecipitation (IP) lipid phosphatase activity assay in ISH-ER α _{WT} cells expressing exogenous PTEN. In Figure 1C it can be seen that PTEN activity significantly decreased concurrently with increased phosphorylation at S380, T382, T383. Taken together, these results indicate that E2 induces PTEN phosphorylation, increases PTEN protein stability and decreases PTEN lipid phosphatase activity. Furthermore, the timing of these actions (30–50 minutes) suggests that rapid, nongenomic signaling mediates these effects.

E2-induced phosphorylation and regulation of PTEN activity is ER α -dependent

E2 has been shown to rapidly signal through ER α [37], estrogen receptor- β (ER β) [67] and an alternate estrogen receptor, G protein-coupled estrogen receptor 1 (GPER) [5, 13]. In order to determine if E2 signals through classical nuclear ER α to regulate PTEN activity, we utilized an ER α negative subclone of Ishikawa cells, the ISH-ER α _{NEG} cells. ISH-ER α _{NEG} cells lack detectable ER α , but express ER β and GPER (Figure 2A). Our pilot studies (Figure 1) utilized transient transfection of PTEN, as Ishikawa endometrial cells are PTEN null due to a stop codon mutation in exon 8 [61]. To facilitate further studies, cell lines that stably express PTEN were developed and these cell lines are used in the remainder of the experiments presented in this manuscript unless otherwise stated (described and characterized in Supplemental Figure 3). ISH-ER α _{NEG} PTEN⁺ cells were starved for 24 hours in serum free media followed by E2 treatment over the indicated time course. Cells were harvested and analyzed for phospho and total PTEN expression via western blotting. Lane 1 of Figure 2B shows lysates prepared from ISH-ER α _{NEG} parental cells transduced with viral particles expressing an empty pCDH vector (EV). In the ISH-ER α _{NEG} PTEN⁺ cells basal PTEN phosphorylation was observed (0 minute time point), however E2 stimulation did not induce additional phosphorylation of PTEN at residues S380, T382, T383 (10–50 minute time points). The corresponding graph shows the average of phospho-PTEN normalized to the GAPDH loading control from 5 independent experiments. Additionally, using a total PTEN antibody we show that PTEN protein levels did not increase in ISH-ER α _{NEG} PTEN⁺ cells upon E2 stimulation (Figure 2C). As a control, similar experiments were conducted concurrently using the ISH-ER α _{WT} PTEN⁺ cells. In the control experiments increased PTEN C-terminal phosphorylation and increased total PTEN protein were observed with E2 stimulation (Supplemental Figure 3). These data show that E2 signals through ER α , but not ER β or GPER, to modulate PTEN phosphorylation and protein stability.

Cytosolic ER α signaling is sufficient to mediate PTEN regulation

To directly test whether E2 regulates PTEN phosphorylation and activity exclusively through cytosolic signaling mechanisms, we developed a PTEN positive Ishikawa cell line that stably expresses an exogenous ER α mutant, lacking the nuclear localization sequence (ISH-ER α _{NLS} PTEN⁺). Characterization of this cell line is shown in Figure 3A and B. Figure 3A shows the results of a western blot using whole cell lysates. ER α _{NLS} migrates approximately 5 kDa lower than ER α _{WT} due to the nuclear localization sequence deletion (amino acids 252 through 303) [65]. Figure 3B shows the results of cellular fractionation followed by Western blotting of the cytosolic and nuclear lysates of ISH-ER α _{NLS} PTEN⁺

and ISH-ER α_{WT} PTEN⁺ cells. GAPDH and TATA binding protein were used as markers to assess cytosolic and nuclear fraction purity. It can be seen that stimulation with E2 does not lead to ER α_{NLS} nuclear accumulation (Figure 3B, top panel). As a control, ISH-ER α_{WT} PTEN⁺ cells were also fractionated, and E2 induced the expected nuclear accumulation of ER α_{WT} (Figure 3B, lower panel). Additionally, in transcription assays using an estrogen receptor element-luciferase reporter construct, we observed no E2-stimulated transcription activity in the ISH-ER α_{NLS} PTEN⁺ cells when compared to ISH-ER α_{WT} PTEN⁺ cells (not shown). Taken together, these data demonstrate that ISH-ER α_{NLS} PTEN⁺ cells express transcriptionally incompetent ER α that do not translocate to the nucleus with E2 treatment. As such, they provide a useful model for studying cytosolic ER α signaling.

We used the ISH-ER α_{NLS} PTEN⁺ cells to exclude potential nuclear contributions of E2/ER α signaling to the PTEN regulatory residues S380, T382, T383. ISH-ER α_{NLS} PTEN⁺ cells were starved in serum free media for 24 hours, treated with E2 and harvested at 0, 10, 30 and 50 minutes, followed by western blotting for PTEN regulatory phospho-residues. Figure 3C shows a representative western blot of phospho-PTEN (S380, T382, T383) in cells expressing the cytosolic only ER α_{NLS} mutant. We observed a 2 fold increase in phospho-PTEN levels, indicating that nuclear ER α is not necessary for E2/ α ER signaling to PTEN carboxy tail regulatory residues. The corresponding graph shows the fold change in phospho-PTEN levels normalized to the GAPDH loading control from 5 independent experiments. In order to determine if the ER α_{NLS} mutant also conferred increased PTEN protein stability, the same lysates were probed with an antibody against total PTEN (Figure 3D). We observed increased protein stability with E2 stimulation. The graph in Figure 3D shows the fold change in total PTEN normalized to the GAPDH loading control from 9 independent experiments. Taken together, the results in Figure 3C and D demonstrate that rapid, non-nuclear E2/ER α signaling mediates PTEN phosphorylation at key negative regulatory residues, and increases PTEN stability.

E2-induced activation of AKT requires PTEN

PTEN lipid phosphatase activity antagonizes the PI3K/AKT signaling axis [33, 52, 59]. Therefore, negative regulation of PTEN by E2 is predicted to lead to increased AKT activity. In order to determine if E2/ER α -dependent negative regulation of PTEN causes increased AKT activity, we treated ISH-ER α_{WT} PTEN⁺ cells and ISH-ER α_{NLS} PTEN⁺ cells with E2, harvested lysates at 0, 10, 30 and 50 minutes and probed for phospho-AKT (S473) and total AKT. Figure 4A shows a representative western blot. The graph below shows the average fold change in phospho-AKT normalized to GAPDH from 4 independent experiments. E2 treatment in ISH-ER α_{WT} PTEN⁺ cells lead to an average 1.5 fold increase in AKT phosphorylation at serine 473, a phospho-residue associated with AKT activation. However, no change was observed in total AKT levels (not shown).

In order to confirm that non-nuclear actions of ER α are responsible for increased AKT phosphorylation, we performed similar experiments using the ISH-ER α_{NLS} PTEN⁺ cells. Figure 4B shows a representative western blot for phospho-AKT. The corresponding graph shows the average fold change in phospho-AKT normalized to GAPDH from 6 independent experiments. We observed an average 2 fold increase in AKT phosphorylation in response

to E2 stimulation in our cell line expressing the cytosolic only, deleted NLS ER α mutant. Total AKT levels did not change with E2 stimulation (not shown). These data indicate that the cytosolic actions of ER α are sufficient to promote E2-stimulated AKT phosphorylation.

Our data show that E2/ER α directly modulates PTEN activity, and we observed rapid increases in AKT-phosphorylation with E2 treatment. However, rapid E2/ER α signaling has been shown to activate AKT directly by interacting with the p85 regulatory subunit of PI3K [6, 50, 34]. In order to show that E2-induced AKT phosphorylation in EC cells is due to ER α acting on PTEN, and not PI3K, we examined the effect of E2 on AKT phosphorylation status in PTEN null cells. ISH-ER α _{WT} PTEN_{NEG} cells were treated with E2, harvested, and phospho-AKT status, as well as total AKT levels, were analyzed using western blotting (Figure 4C). In the representative western blot, it can be seen that E2 treatment does not increase phosphorylation of AKT above baseline in ER α wild type cells lacking PTEN. Total AKT levels also did not change upon E2 treatment (not shown). The corresponding graph shows the average fold change in phospho-AKT normalized to GAPDH from 3 independent experiments. In order to determine if cytosolic-only ER α signaling impacted AKT phosphorylation in the absence of PTEN, identical experiments were performed using the PTEN negative, ER α NLS mutant cell line (Figure 4D). In these experiments, it is unclear whether the PTEN-independent decrease in phospho-AKT (10 and 30 minutes) is biologically relevant, or is a result of enhanced cytosolic ER α signaling. Total AKT levels did not significantly increase above baseline or decrease below baseline (data not shown). Taken together, the results in Figure 4 show that E2/ER α signaling increases AKT phosphorylation via negative regulatory actions on PTEN and requires only cytosolic ER α mechanisms.

ER α forms a complex with protein kinase CK2 and PTEN in endometrial cancer cells

The C-terminal tail of PTEN contains protein kinase CK2 (formerly termed “casein kinase 2”) consensus sequences that encompass the regulatory residues S380, T382, T383 [55]. Additionally, *in vitro* studies indicate that this region of PTEN can be phosphorylated by CK2 [55]. We observed that the CK2 inhibitor, (E)-3-(2,3,4,5-Tetrabromophenyl) acrylic acid (TBCA), blocked E2-induced PTEN phosphorylation of S380, T382, T383 and E2-induced increases in total PTEN (Supplemental Figure 1). As ER α is thought to promote rapid signaling through interactions with cytosolic kinases, we sought to determine if ER α and CK2 α (the catalytic subunit of the CK2 holoenzyme) form a complex in EC cells using co-immunoprecipitation (co-IP). ISH-ER α _{WT} PTEN⁺ cells were serum starved for 24 hours and treated with E2 for 0, 10, 30 or 50 minutes, followed by IP with an antibody specific to ER α . Normal IgG was used as a control to show antibody specificity. Lysates were analyzed via Western blot using an antibody against CK2 α . In ISH-ER α _{WT} PTEN⁺ cells CK2 α co-immunoprecipitated with ER α in both the absence and presence of E2 (Figure 5A). To determine if ER α and PTEN form a complex, we performed co-IP experiments using an antibody against PTEN, and probed the resultant western blots with an antibody against ER α . Figure 5B shows that ER α and PTEN form a complex only in the presence of E2. Our co-IP experiments show that ER α and CK2 α exist in a complex in both the presence and absence of E2 and that E2 promotes the formation of a complex that contains both ER α and PTEN.

As the ER α nuclear localization sequence mutant promoted phosphorylation of PTEN on regulatory residues in response to E2, we repeated the co-IP experiments described in Figures 5A and B using the ISH-ER α NLS PTEN+ cell line. The ER α NLS deletion mutant also constitutively complexes with CK2 α and forms a complex with PTEN in an E2-dependent manner (Figure 5C and D, respectively). These data provide evidence that deletion of amino acids 252 through 303 does not abolish the ability of ER α NLS to complex with both CK2 α and PTEN. We propose that E2 exposure recruits PTEN to the ER α :CK2 α complex, thereby providing a potential mechanism by which rapid E2/ER α actions lead to phosphorylation and negative regulation of PTEN activity. However, further molecular studies are required to confirm this pathway.

Long term E2 exposure correlates with increased phospho-PTEN, total PTEN and phospho-AKT in normal murine endometrial cells

The data in Figures 1 through 5 utilize EC cell culture models to show that rapid E2 actions can regulate PTEN phosphorylation, stability and activity. Additionally, these data show that ER α (and not ER β or GPER) is necessary for E2 regulation of PTEN phosphorylation, and that only cytosolic actions of ER α are required. Using these models, we show that E2-stimulated reduction in PTEN lipid phosphatase activity results in increased AKT phosphorylation at the S473 activation site. To determine a potential role for E2 regulation of PTEN *in vivo*, we used immunohistochemistry (IHC) to examine phospho-PTEN (S380, T382, T383), total PTEN and phospho-AKT (S473) status in mice uteri exposed to long term E2 treatment as described [17, 46]. Figure 6A shows representative images of uterine glands stained for phospho-PTEN from ovariectomized mice (Figure 6A, OVX) or from mice exposed to sustained E2 for 8 weeks (Figure 6A, E2). It can be seen that the columnar endometrial cells lining the glands exhibit increased phospho-PTEN staining in the uteri exposed to E2 when compared to uteri from ovariectomized mice. As endometrial cells in ovariectomized mice are smaller than endometrial cells of mice exposed to E2, the insert shows a 2.5 magnification to allow comparison at the individual cell level. The corresponding graph shows the average sum intensity per gland area of 9 ovx or E2 treated mice. The phospho-PTEN sum intensity/gland area was 2.3 times greater in the uteri of mice exposed to 8 weeks of E2 treatment as compared to the ovariectomized control mice. Figure 6B shows the results of IHC staining of mouse uteri with an antibody against total PTEN. As shown in the representative images and corresponding graph, uterine glands from mice exposed to E2 for 8 weeks showed an increase in total PTEN when compared to the ovariectomized control mice.

We next sought to determine if phospho-PTEN observed in endometrial glands from mice exposed to sustained levels of E2, correlated with the predicted increase in AKT activity. To this end we stained uteri from ovariectomized and E2 exposed mice with an antibody directed against phospho-AKT (S473). Quantification of representative glands yielded a 1.3 fold increase in phospho-AKT in E2 exposed endometrial glands when compared to ovariectomized controls (Figure 6C).

Taken together, the data in Figure 6 show that sustained E2 exposure leads to increased phospho-PTEN, total PTEN and phospho-AKT in the context of a normal mouse uterus.

While the IHC data are correlative, they extend the molecular signaling data obtained from our cell lines and suggest that E2 may regulate PTEN and AKT *in vivo*.

Discussion

Our discovery that rapid E2 signaling decreases PTEN tumor suppressive activity is an extraordinarily relevant finding within the context of the endometrium, as hyperestrogenicity, or unopposed E2 stimulation, is thought to cause Type 1 EC [26, 23, 35]. It has long been known that E2 activates ER transcriptional activity to promote proliferation in normal uterine epithelial cells, and that Type 1 EC is dependent on E2 signaling [21, 26]. However, the effects of transcription-independent E2 signaling on the endometrium or endometrial carcinoma have not been fully investigated. Our data in human EC cells demonstrate that rapid E2 action leads to decreased PTEN activity. Additionally we show that sustained E2 treatment in a mouse model correlates with increased phospho-PTEN and decreased PTEN activity as assessed by phospho/active AKT status. While the majority of our studies focus on endometrial cancer, we have observed similar results in MCF7 breast cancer cells (Supplemental Figure 2). These data provide a second pathway by which E2 exposure may increase the risk of steroid-dependent cancers, including breast and endometrial.

E2 treatment also lead to the predicted increase in PTEN protein stability. In the context of the normal endometrium, high levels of PTEN protein may be protective against potential aberrant proliferation. Our mice data support the conclusion that E2 exposure corresponds with PTEN phosphorylation and decreased function as assessed by activity of the downstream target, AKT. Essentially, the function of high levels of low activity PTEN observed during the proliferative phase of the normal menstrual cycle may function as a “brake” in the event of aberrant proliferative signals. Hyperestrogenicity may shift the amount of inactive PTEN beyond the normal protective range, causing activation of AKT signaling, thereby increasing and risk for hyperplasia and endometrial cancer.

We show that E2 negatively regulates PTEN activity solely through ER α cytosolic mechanisms in EC cells. Jakacka et al. have shown that mice expressing mutant ER α , which are unable to bind estrogen response elements (NERKI^{+/-} mouse), show significantly increased uterine weight as well as cystic endometrial hyperplasia, a precursor to endometrial cancer [22]. Furthermore, microarray data from NERKI^{+/-} mice uteri, show E2-dependent regulation of the Wnt/ β -catenin signaling pathway, a pathway highly misregulated in many cancers [63, 10, 19]. The impact of rapid E2 signaling in the uterus may be an underappreciated, yet significant, contributor to endometrial cancer initiation and progression.

In contrast, in a mouse model expressing membrane only ER α (MOER mouse) only atrophic uteri were observed [42]. Additionally, when mice expressing wild type ER α were treated with an estrogen-dendrimer conjugate, which sequesters ER α in the cytosol, no uterine proliferation was noted [8]. Therefore, our understanding of the role of rapid, nongenomic E2 signaling and how it contributes to normal uterine development as well as uterine carcinogenesis is only beginning to be understood.

Our data show that E2 stimulates increased PTEN phosphorylation at S380, T382, and T383, leading to decreased activity and consequent activation of AKT in endometrial cancer cells. Additionally, our IHC data show significant increases in phospho-PTEN (inactive) and phospho-AKT (active) in mice exposed to sustained circulating E2 for 8 weeks [45, 17]. Hyperactivation of AKT promotes cancer through several pathways [25, 49]. AKT enacts its proliferative effects through inhibition of p27, resulting in a loss of G1 arrest in breast cancer cells, and promotes VEGF production and angiogenesis in prostate cancer cell [30, 69]. Upregulated phospho-AKT is also positively correlated with increased survivin expression in endometrial tumors, causing further decreases in apoptosis through inhibition of caspase activation [41, 54]. Overall, increased AKT signaling, a result of E2-induced PTEN inactivation, may contribute to increased endometrial cancer risk through a number of signaling pathways.

E2 treatment resulted in reduced PTEN activity in endometrial cancer cells. However, PTEN activity was not fully abolished. While complete loss of PTEN is seen in many human cancers, it is becoming clear that incremental changes in PTEN activity may significantly impact susceptibility to a variety of cancers, including endometrial cancer [3, 56]. *Pten*^{+/-} haploinsufficient mice, which express 50% of normal PTEN levels and show high levels of active AKT staining, show increased incidence of endometrial neoplasia [11, 43, 60, 24]. Furthermore, endometrial tumors from the *Pten*^{+/-} haploinsufficient mice show elevated phospho-AKT levels as well as phosphorylation of the Bcl-2-associated death promoter (Bad) protein, a known target of AKT that allows for evasion of apoptosis through binding of 14-3-3 proteins [66, 24]. Genetically engineered *Pten* hyper (*Pten*^{hy/+}) mice, which express 80% PTEN mRNA and protein when compared to wild type mice, develop endometrial atypical complex hyperplasia, a precursor to endometrial cancer [3]. Mammary glands from *Pten* hyper mice displayed an increase in proliferative index, and the majority of female mice developed mammary tumors [3]. Additionally, *Pten* hypo (*Pten*^{hy/-}) mice (20% PTEN expression) develop prostate hyperplasia and invasive prostate cancer [56]. Therefore, growing evidence demonstrates that even slight alterations in PTEN activity levels have significant biological consequences in the uterine environment as well as in other reproductive tissues.

We observed that inhibition of CK2 with TBCA abolished E2 induced phosphorylation of PTEN, and PTEN is a known substrate of CK2. A recent report by Hagan et al. shows that progesterone receptor indirectly interacts with CK2 via a common docking domain on the N-terminus of progesterone receptor-B [16]. Furthermore, CK2 has been shown to phosphorylate ER α on S282 and S559 *in vivo* and *in vitro* [64]. We have shown that CK2 phosphorylates PTEN in our cells, however, it is possible that CK2 also acts on ER α S282 and S559 to modulate rapid ER α signaling to PTEN. Additionally, Lin et al. have shown that the androgen receptor and PTEN directly interact through the androgen receptor DBD and N-terminus phosphatase domain of PTEN (amino acids 110-163) [31]. As nuclear receptors are highly conserved, we sought to determine if similar interactions may provide a potential mechanism by which rapid E2/ER α interactions regulate PTEN. We observed a constitutive cytosolic complex containing ER α and CK2, and an E2-dependent complex formation between ER α and PTEN. Our data suggest that E2 exposure recruits PTEN to a

cystolic complex containing ER α and CK2 α and provide a potential mechanism by which rapid E2 signaling regulates PTEN.

While our studies focus on endometrial cancer cells, we have observed similar results in MCF7 breast cancer cells (Supplemental Figure 2). These data support observations in the *Pten* hyper mice as a reduction in PTEN correlated with an increase in phospho-AKT (S473) and Ki-67 in mammary tumors [3]. Additionally, pilot studies using microdissected epithelial cells from random periareolar fine needle aspiration samples have shown that women at risk for breast cancer, have elevated levels of phosphorylated PTEN (S380), total PTEN and active phospho-AKT (S473) [20]. These studies suggest that E2 regulation of PTEN may be an important mechanism in a number of steroid responsive tissues. Furthermore, other steroids and steroid analogs may also regulate PTEN.

E2 has been thought to be a risk factor for uterine cancer solely through proliferative mechanisms. Our data demonstrate that cytosolic E2/ER α actions decrease PTEN tumor suppressive activity, thereby providing an alternate mechanism by which hyperestrogenicity may increase the risk for EC. Current treatment of EC involves hysterectomy, which is costly and associated with high morbidity and mortality. Our research suggests that expanding studies focused on transcription-independent signaling of E2 may broaden our understanding of E2/ER interaction with pathways involved in cancer initiation and progression. Therefore elucidating the role(s) of rapid E2/ER α signaling may uncover new prognostic markers, reveal targetable pathways, and allow for individualized treatment of women with uterine cancer.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. Jennifer Richer for providing uterine samples and Nicole Spoelstra from the University of Colorado Cancer Center Tissue Biobanking and Processing Core. We would like to thank Dr. Joanne Masterson for training and guidance in using the Nikon Microscope and NIS-Elements Imaging Software. We would like to thank Dr. Louise Glover for assistance in generating pCDH-PTEN plasmids and general advice in molecular technologies. We thank Dr. Eric Campbell for his assistance and thoughtful discussions. We thank Dr. Pierre Chambon (Institute de Chimie Biologique, France) for providing the pSG5-HE241G vector (ER α NLS).

This work was supported by the National Institutes of Health/National Cancer Institute (R01 CA125427), the University of Colorado Obstetrics and Gynecology department Academic Enrichment Fund, and the National Institutes of Health/National Center for Advancing Translational Sciences Colorado Clinical and Translational Sciences Institute (TL1 TR001081).

References

1. Abd El-Maqsoud NM, El-Gelany S. Differential Expression Patterns of PTEN in Cyclic, Hyperplastic and Malignant Endometrium: Its Relation with ER, PR and Clinicopathological Parameters. *J Egypt Natl Canc Inst.* 2009; 21(4):323–331. [PubMed: 21415869]
2. Acconcia F, Barnes CJ, Kumar R. Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. *Endocrinology.* 2006; 147(3):1203–1212. en.2005-1293 [pii]. 10.1210/en.2005-1293 [PubMed: 16339197]

3. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, et al. Subtle variations in Pten dose determine cancer susceptibility. *Nat Genet.* 2010; 42(5):454–458. [pii]. 10.1038/ng.556ng.556 [PubMed: 20400965]
4. American Cancer Society. [Accessed 03/10/2014.] What are the key statistics about endometrial cancer?. 2014. <http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-key-statistics>
5. Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. *Genomics.* 1997; 45(3):607–617. S0888-7543(97)94972-7 [pii]. 10.1006/geno.1997.4972 [PubMed: 9367686]
6. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. *The EMBO journal.* 2001; 20(21):6050–6059. 10.1093/emboj/20.21.6050 [PubMed: 11689445]
7. Chakravarty D, Nair SS, Santhamma B, Nair BC, Wang L, Bandyopadhyay A, Agyin JK, et al. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. *Cancer research.* 2010; 70(10):4092–4101. 10.1158/0008-5472.CAN-09-3834 [PubMed: 20460518]
8. Chambliss KL, Wu Q, Oltmann S, Konanah ES, Umetani M, Korach KS, Thomas GD, et al. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. *J Clin Invest.* 2010; 120(7):2319–2330. 38291 [pii]. 10.1172/JCI38291 [PubMed: 20577047]
9. Cormack BP, Valdivia RH, Falkow S. FACS-optimized mutants of the green fluorescent protein (GFP). *Gene.* 1996; 173(1):33–38. doi:0378111995006850 [pii]. [PubMed: 8707053]
10. Dey N, Barwick BG, Moreno CS, Ordanic-Kodani M, Chen Z, Oprea-Ilie G, Tang W, et al. Wnt signaling in triple negative breast cancer is associated with metastasis. *BMC Cancer.* 2013; 13(1): 537. 1471-2407-13-537 [pii]. 10.1186/1471-2407-13-537 [PubMed: 24209998]
11. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. *Nature genetics.* 1998; 19(4):348–355. 10.1038/1235 [PubMed: 9697695]
12. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. *Endocr Relat Cancer.* 2000; 7(4):227–242. [PubMed: 11174845]
13. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. *Molecular endocrinology.* 2002; 16(1): 70–84. 10.1210/mend.16.1.0758 [PubMed: 11773440]
14. Ganapathy V, Banach-Petrosky W, Xie W, Kareddula A, Nienhuis H, Miles G, Reiss M. Luminal breast cancer metastasis is dependent on estrogen signaling. *Clin Exp Metastasis.* 2012; 29(5): 493–509. 10.1007/s10585-012-9466-4 [PubMed: 22427027]
15. Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, Garibaldi S, Mannella P, et al. Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. *PLoS One.* 2008; 3(5):e2238. 10.1371/journal.pone.0002238 [PubMed: 18493596]
16. Hagan CR, Knutson TP, Lange CA. A Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. *Nucleic Acids Res.* 2013; 41(19):8926–8942. gkt706 [pii]. 10.1093/nar/gkt706 [PubMed: 23921636]
17. Harvell DM, Richer JK, Allred DC, Sartorius CA, Horwitz KB. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. *Endocrinology.* 2006; 147(2):700–713. en.2005-0617 [pii]. 10.1210/en.2005-0617 [PubMed: 16239301]
18. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. *J Clin Oncol.* 2006; 24(29):4783–4791. 24/29/4783 [pii]. 10.1200/JCO.2006.06.7173 [PubMed: 17028294]
19. Hewitt SC, O'Brien JE, Jameson JL, Kissling GE, Korach KS. Selective disruption of ER{alpha} DNA-binding activity alters uterine responsiveness to estradiol. *Molecular endocrinology.* 2009; 23(12):2111–2116. 10.1210/me.2009-0356 [PubMed: 19812388]

20. Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF 3rd, Wulfschlegel J, Liotta LA, et al. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. *Breast cancer research and treatment*. 2012; 132(2):487–498.10.1007/s10549-011-1609-9 [PubMed: 21647677]
21. Ishiwata I, Nozawa S, Okumura H. Effects of 17beta-estradiol and progesterone on growth and morphology of human endometrial carcinoma cells in vitro. *Cancer Res*. 1977; 37(12):4246–4249. [PubMed: 562709]
22. Jakacki M, Ito M, Martinson F, Ishikawa T, Lee EJ, Jameson JL. An estrogen receptor (ER)alpha deoxyribonucleic acid-binding domain knock-in mutation provides evidence for nonclassical ER pathway signaling in vivo. *Molecular endocrinology*. 2002; 16(10):2188–2201.10.1210/me.2001-0174 [PubMed: 12351685]
23. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. *Cancer Epidemiol Biomarkers Prev*. 2002; 11(12):1531–1543. [PubMed: 12496040]
24. Kanamori Y, Kigawa J, Itamochi H, Shimada M, Takahashi M, Kamazawa S, Sato S, Akeshima R, Terakawa N. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. *Clin Cancer Res*. 2001; 7(4):892–895. [PubMed: 11309338]
25. Kanamori Y, Kigawa J, Itamochi H, Shimada M, Takahashi M, Kamazawa S, Sato S, Akeshima R, Terakawa N. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2001; 7(4):892–895. [PubMed: 11309338]
26. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. *Br J Cancer*. 1988; 57(2):205–212. [PubMed: 3358913]
27. Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, Jordan VC, Bradford AP. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. *Gynecol Oncol*. 2012; 127(1):241–248. S0090-8258(12)00455-6 [pii]. 10.1016/j.ygyno.2012.06.017 [PubMed: 22710073]
28. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, Rhee SG. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. *Proc Natl Acad Sci U S A*. 2004; 101(47):16419–16424. 0407396101 [pii]. 10.1073/pnas.0407396101 [PubMed: 15534200]
29. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. *Cell*. 1999; 99(3):323–334. S0092-8674(00)81663-3 [pii]. [PubMed: 10555148]
30. Liang J, Zubovitz J, Petrucelli T, Katchkov R, KConnor M, Han K, Lee JH, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. *Nature medicine*. 2002; 8(10):1153–1160.10.1038/nm761
31. Lin HK, Hu YC, Lee DK, Chang C. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. *Mol Endocrinol*. 2004; 18(10):2409–2423. me.2004-0117 [pii]. 10.1210/me.2004-0117 [PubMed: 15205473]
32. Maccario H, Perera NM, Gray A, Downes CP, Leslie NR. Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress. *J Biol Chem*. 2010; 285(17):12620–12628. M109.072280 [pii]. 10.1074/jbc.M109.072280 [PubMed: 20177066]
33. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem*. 1998; 273(22):13375–13378. [PubMed: 9593664]
34. Mannella P, Brinton RD. Estrogen receptor protein interaction with phosphatidylinositol 3-kinase leads to activation of phosphorylated Akt and extracellular signal-regulated kinase 1/2 in the same population of cortical neurons: a unified mechanism of estrogen action. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2006; 26(37):9439–9447.10.1523/JNEUROSCI.1443-06.2006 [PubMed: 16971528]

35. McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. *American journal of epidemiology*. 1996; 143(12):1195–1202. [PubMed: 8651218]
36. Merritt MA, Cramer DW. Molecular pathogenesis of endometrial and ovarian cancer. *Cancer Biomark*. 2010; 9(1–6):287–305. 3318T6184L471041 [pii]. 10.3233/CBM-2011-0167 [PubMed: 22112481]
37. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. *EMBO J*. 1996; 15(6):1292–1300. [PubMed: 8635462]
38. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Eng C. Changes in endometrial PTEN expression throughout the human menstrual cycle. *J Clin Endocrinol Metab*. 2000; 85(6):2334–2338. [PubMed: 10852473]
39. Odriozola L, Singh G, Hoang T, Chan AM. Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain. *J Biol Chem*. 2007; 282(32):23306–23315. M611240200 [pii]. 10.1074/jbc.M611240200 [PubMed: 17565999]
40. Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, Furnari FB. PCAF modulates PTEN activity. *J Biol Chem*. 2006; 281(36):26562–26568. M605391200 [pii]. 10.1074/jbc.M605391200 [PubMed: 16829519]
41. Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X. Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3. *Int J Gynecol Pathol*. 2005; 24(3):247–253. 00004347-200507000-00008 [pii]. [PubMed: 15968200]
42. Pedram A, Razandi M, Kim JK, O'Mahony F, Lee EY, Luderer U, Levin ER. Developmental phenotype of a membrane only estrogen receptor alpha (MOER) mouse. *J Biol Chem*. 2009; 284(6):3488–3495. M806249200 [pii]. 10.1074/jbc.M806249200 [PubMed: 19054762]
43. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. *Proc Natl Acad Sci U S A*. 1999; 96(4):1563–1568. [PubMed: 9990064]
44. Razandi M, Pedram A, Levin ER. Estrogen signals to the preservation of endothelial cell form and function. *J Biol Chem*. 2000; 275(49):38540–38546. M007555200 [pii]. 10.1074/jbc.M007555200 [PubMed: 10988297]
45. Sartorius CA, Harvell DM, Shen T, Horwitz KB. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. *Cancer research*. 2005; 65(21):9779–9788.10.1158/0008-5472.CAN-05-0505 [PubMed: 16266999]
46. Sartorius CA, Harvell DM, Shen T, Horwitz KB. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. *Cancer Res*. 2005; 65(21):9779–9788. 65/21/9779 [pii]. 10.1158/0008-5472.CAN-05-0505 [PubMed: 16266999]
47. Sartorius CA, Shen T, Horwitz KB. Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. *Breast Cancer Res Treat*. 2003; 79(3):287–299. [PubMed: 12846413]
48. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. *Mod Pathol*. 2000; 13(3):295–308.10.1038/modpathol.3880051 [PubMed: 10757340]
49. Shtilbans V, Wu M, Burstein DE. Current overview of the role of Akt in cancer studies via applied immunohistochemistry. *Annals of diagnostic pathology*. 2008; 12(2):153–160.10.1016/j.anndiagpath.2007.12.001 [PubMed: 18325479]
50. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. *Nature*. 2000; 407(6803):538–541.10.1038/35035131 [PubMed: 11029009]
51. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. *Clin Cancer Res*. 2012; 18(21):5856–5864. 1078-0432.CCR-12-0662 [pii]. 10.1158/1078-0432.CCR-12-0662 [PubMed: 23082003]
52. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the

- tumor suppressor PTEN. *Cell*. 1998; 95(1):29–39. S0092-8674(00)81780-8 [pii]. [PubMed: 9778245]
53. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, Gavrilova N, Mueller B, Liu X, Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. *Proc Natl Acad Sci U S A*. 1999; 96(11):6199–6204. [PubMed: 10339565]
 54. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. *Cancer Res*. 1998; 58(23):5315–5320. [PubMed: 9850056]
 55. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. *J Biol Chem*. 2001; 276(2):993–998. M009134200 [pii]. 10.1074/jbc.M009134200 [PubMed: 11035045]
 56. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, et al. Pten dose dictates cancer progression in the prostate. *PLoS Biol*. 2003; 1(3):E59.10.1371/journal.pbio.0000059 [PubMed: 14691534]
 57. U.S. Cancer statistics working group. United States Cancer Statistics: 1999–2010 incidence and mortality web-based report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; <http://www.cdc.gov/uscs> [Accessed 2013.]
 58. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. *Mol Cell Biol*. 2000; 20(14):5010–5018. [PubMed: 10866658]
 59. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. *Biochimica et biophysica acta*. 2000; 1470(1):M21–35. [PubMed: 10656987]
 60. Vilgelm A, Lian Z, Wang H, Beauparlant SL, Klein-Szanto A, Ellenson LH, Di Cristofano A. Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. *Cancer Res*. 2006; 66(7):3375–3380. 66/7/3375 [pii]. 10.1158/0008-5472.CAN-05-4019 [PubMed: 16585156]
 61. Wan X, Yokoyama Y, Shinohara A, Takahashi Y, Tamaya T. PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway. *Cell Death Differ*. 2002; 9(4):414–420.10.1038/sj/cdd/4400982 [PubMed: 11965494]
 62. Watson CS, Jeng YJ, Kochukov MY. Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation. *FASEB J*. 2008; 22(9):3328–3336. fj.08-107672 [pii]. 10.1096/fj.08-107672 [PubMed: 18541692]
 63. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. *Gastroenterology*. 2012; 142(2):219–232. S0016-5085(11)01636-2 [pii]. 10.1053/j.gastro.2011.12.001 [PubMed: 22155636]
 64. Williams CC, Basu A, El-Gharbawy A, Carrier LM, Smith CL, Rowan BG. Identification of four novel phosphorylation sites in estrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. *BMC Biochem*. 2009; 10:36. 1471-2091-10-36. 10.1186/1471-2091-10-36 [PubMed: 20043841]
 65. Ylikomi T, Bocquel MT, Berry M, Gronemeyer H, Chambon P. Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors. *EMBO J*. 1992; 11(10):3681–3694. [PubMed: 1327748]
 66. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). *Cell*. 1996; 87(4):619–628. S0092-8674(00)81382-3 [pii]. [PubMed: 8929531]
 67. Zhang G, Liu X, Farkas AM, Parwani AV, Lathrop KL, Lenzner D, Land SR, Srinivas H. Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. *Molecular endocrinology*. 2009; 23(2):146–156.10.1210/me.2008-0431 [PubMed: 19106194]
 68. Zheng S, Huang J, Zhou K, Zhang C, Xiang Q, Tan Z, Wang T, Fu X. 17beta-Estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin. *PLoS One*. 2011; 6(7):e22439. PONE-D-11-01198 [pii]. 10.1371/journal.pone.0022439 [PubMed: 21818323]

69. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. *Cancer research*. 2000; 60(6):1541–1545. [PubMed: 10749120]

Figure 1.

E2 stimulation increases phospho-PTEN and total PTEN levels but decreases lipid phosphatase activity. (A) ISH-ER α_{WT} cells were transiently transfected with a GFP-PTEN expression construct or empty vector (EV) followed by starvation for 24 hours in serum free media. Starved cells were treated with E2 for 0, 10, 30 or 50 minutes. Cells were harvested and analyzed via western blotting with an antibody specific to phospho-PTEN (S380, T382, T383) or (B) total PTEN. Corresponding graphs to the right represent quantification of fold change $\pm$ St. Dev. (n=3) of (A) phospho-PTEN or (B) total PTEN normalized to β -actin. (* P <0.05 by ANOVA) (C) ISH-ER α_{WT} cells were transiently transfected with a GFP-PTEN expression construct or empty vector (EV) followed by E2 treatment for 0, 10 or 50 minutes. Cells were lysed in non-denaturing lysis buffer followed by immunoprecipitation of exogenous PTEN. Immunoprecipitated PTEN was then exposed to PtdIns(3,4,5)P₃ substrate. Resulting phosphatase activity was then measured via malachite colorimetric assay to calculate picomoles of free phosphate. Graph represent quantification of fold change $\pm$ St. Dev. (n=3) of free phosphate (pmol). (** P <0.01 by ANOVA).

Figure 2.

E2 regulation of PTEN is ER α -dependent. (A) Western blot analysis of whole cell lysates from ISH-ER α WT and ISH-ER α NEG cells with antibodies specific to ER α , ER β , GPER and GAPDH. (B) ISH-ER α NEG PTEN+ cells were starved in serum free media for 24 hours followed by E2 treatment for 0, 10, 30 or 50 minutes. ISH-ER α NEG PTEN+ cells and ISH-ER α NEG empty vector control cells (EV) were harvested and analyzed via western blotting with an antibody specific to phospho-PTEN (S380, T382, T383) or (C) total PTEN. Corresponding graphs to the right represent quantification of fold change $\pm$ St. Dev. (n=5) of (A) phospho-PTEN or (B) total PTEN normalized to GAPDH. (P =ns, by ANOVA).

Figure 3.

E2/ERα cytosolic actions are sufficient to regulate PTEN phosphorylation and protein stability. (A) Western blot analysis of whole cell lysates from ISH-ERα_{WT} and ISH-ERα_{NLS} cells with antibodies specific to ERα and GAPDH. (B) ISH-ERα_{NLS} cells (top panel) and ISH-ERα_{WT} cells (bottom panel) were starved in serum free media for 24 hours followed by E2 treatment for 0, 10 or 50 minutes. Cell lysates were collected for biochemical subcellular fractionation. Cytoplasmic (left panel) and nuclear (right panel) fractions were analyzed via western blotting. Compartmentalization of ERα over E2 treatment times was assessed by immunoblotting with an antibody specific to ERα. Fractionation purity was determined using antibodies specific to nuclear protein, TATABP, and cytosolic protein, GAPDH. (C) ISH-ERα_{NLS} PTEN+ cells were starved in serum free media for 24 hours followed by E2 treatment for 0, 10, 30 or 50 minutes. ISH-ERα_{NLS} PTEN+ cells and ISH-ERα_{NLS} empty vector control cells (EV) were harvested and analyzed via western blotting with an antibody specific to phospho-PTEN (S380, T382, T383) or (D) total PTEN. Corresponding graphs below western blot image represent quantification of fold change ± St. Dev. of (C) phospho-PTEN or (D) total PTEN normalized to GAPDH. (n=5 and 9, respectively. ***P*<0.01 by ANOVA).

Figure 4.

E2 stimulation increases phospho-AKT in a PTEN-dependent manner. (A) ISH-ER α_{WT} PTEN⁺ and (B) ISH-ER $\alpha_{\Delta NLS}$ PTEN⁺ were starved in serum free media for 24 hours followed by E2 treatment for 0, 10, 30 or 50 minutes. Cells were harvested and analyzed via western blotting with an antibody specific to phospho-AKT (473) and total AKT.

Corresponding graphs below western blot image represent quantification of fold change $\pm$ St. Dev. of phospho-AKT normalized to GAPDH. (ISH-ER α_{WT} PTEN⁺ cells, n=4, * P <0.05 by ANOVA, ISH-ER $\alpha_{\Delta NLS}$ PTEN⁺ cells, n=6, *** P <0.001 by ANOVA). (C) ISH-ER α_{WT} PTEN^{NEG} and (D) ISH-ER $\alpha_{\Delta NLS}$ PTEN^{NEG} cells were starved in serum free media for 24 hours followed by E2 treatment for 0, 10, 30 or 50 minutes. Cells were harvested and analyzed via western blotting with an antibody specific to phospho-AKT (473) and total AKT. Corresponding graphs below western blot image represent quantification of fold change $\pm$ St. Dev. (n=3) of phospho-AKT normalized to GAPDH. (ISH-ER α_{WT} PTEN^{NEG} cells P =ns by ANOVA, ISH-ER $\alpha_{\Delta NLS}$ PTEN^{NEG} cells ** P <0.01 by ANOVA).

Quantification of fold change $\pm$ St. Dev. (n=3) of total AKT normalized to GAPDH resulted in P =ns, by ANOVA, in all cell lines (data not shown).

Figure 5.

ERα and CK2α exist in a complex in both absence and presence of E2, while ERα and PTEN form a complex in an E2-dependent manner. (A) ISH-ERα_{WT} PTEN+ and (C) ISH-ERα_{NLS} PTEN+ cells were starved in serum free media for 24 hours followed by E2 treatment for 0, 10, 30 or 50 minutes. Cells were harvested in non-denaturing buffer followed by immunoprecipitation (IP) with an antibody specific to ERα or IgG control antibody. Immunoprecipitates were analyzed via western blotting with an antibody specific to ERα. Co-immunoprecipitation (co-IP) of CK2α was assessed with an antibody specific to CK2α. IgG arrow shows heavy chain IgG from ERα IP antibody (50 kDa). Representative western blot images for (A) ISH-ERα_{WT} PTEN+ cells and (C) ISH-ERα_{NLS} PTEN+ cells shown (n=3). (B) ISH-ERα_{WT} PTEN+ and (D) ISH-ERα_{NLS} PTEN+ cells were starved in serum free media for 24 hours followed by E2 treatment and IP with an antibody specific to PTEN or IgG control antibody. Immunoprecipitates were analyzed via western blotting with an antibody specific to PTEN and co-IP of ERα was assessed with an antibody specific to ERα. IgG arrow shows heavy chain IgG from PTEN IP antibody (50 kDa). Representative western blot images for (B) ISH-ERα_{WT} PTEN+ cells and (D) ISH-ERα_{NLS} PTEN+ cells shown (n=3).

Figure 6.

Unopposed E2 treatment leads to increased phospho-PTEN, total PTEN and phospho-AKT in murine endometrium. Mice were ovariectomized (ovx), or ovariectomized and treated with E2 (E2) for 8 weeks. Uteri from ovx and E2 mice were formalin fixed and paraffin embedded. Sections (5 µm) were stained with antibodies specific for (A) phospho-PTEN (S380, T382, T383), (B) total PTEN and (C) phospho-AKT (S473) and counterstained with hematoxylin. Corresponding graphs to the right represent quantification of sum intensity/gland area $\pm$ St. Dev. (Phospho-PTEN, n=9 ovx, n=9 E2 mice, *** P <0.001 by Student t test, total PTEN, n=6 ovx, n=10 E2 mice, *** P <0.001 by Student t test, phospho-AKT, n=6 ovx n=9 E2 mice, ** P <0.01 by Student t test). Representative fields were taken at x40 magnification. ovx inset gland magnified an additional 2.5x. Scale bar, 100 µm.

Figure 7.

Model of ERα regulation of PTEN. E2-bound ERα induces phosphorylation of PTEN at C-terminus regulatory residues S380, T382, T383 via CK2α. Phosphorylation of PTEN at these residues decreases PTEN lipid phosphatase activity, which leads to downstream activation of AKT signaling.